Compares cost and value of eye injection treatments for wet macular degeneration in France
Studies costs and benefits of anti-VEGF eye injections in adults with untreated age-related macular degeneration.
Plain-language title generated from the registry record
Registry title: Medico-economic Evaluation of Anti-VEGF Treatments in the Treatment of naïve Age-related Macular Degeneration (AMD): a Model Adapted to the French Context
Key facts
- Where
- Amiens, FranceSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT03577041, who can take part
Where in France
- CHU AmiensAmiens, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier Universitaire, Amiens
- Trial code
- NCT03577041
- Record updated
- 15 June 2026
- Original description
Age-related macular degeneration (AMD) is the leading cause of blindness after 50 years in industrialized countries, compromising daily activities and reducing quality of life. And whose treatment is one of the first health expenditures. Since September 2015, Bevacizumab, which does not have marketing authorization in AMD, has been given a temporary recommendation for use. Studies in other countries have shown that bevacizumab is cost-effective in the treatment of AMD compared to other anti-VEGF therapies used.Read full original descriptionShow less
Medico-economic Evaluation of Anti-VEGF Treatments in the Treatment of naïve Age-related Macular Degeneration (AMD): a Model Adapted to the French Context
Age-related macular degeneration (AMD) is the leading cause of blindness after 50 years in industrialized countries, compromising daily activities and reducing quality of life. And whose treatment is one of the first health expenditures. Since September 2015, Bevacizumab, which does not have marketing authorization in AMD, has been given a temporary recommendation for use. Studies in other countries have shown that bevacizumab is cost-effective in the treatment of AMD compared to other anti-VEGF therapies used.
Inclusion: Naive neovascular AMD form of retro localization foveal, unilateral or bilateral (one eye per patient will be studied),; Patients to be treated with intravitreous injections of Bevacizumab or Ranibizumab or Aflibercept,; Patient using effective contraception if he is of childbearing age; Patient informed and not having made his opposition to the research,; Patient under social security scheme.
Exclusion: Previous or current treatment of AMD by intravenous injection of anti-VEGF or surgery dating less than 2 months in the studied eye,; Contraindications to the taking of Bevacizumab or Ranibizumab or Aflibercept,; Known hypersensitivity to pharmaceutical agents used,; Severe active intraocular inflammation, or history autoimmune or idiopathic uveitis,; Active or suspected ocular or periocular infection,; Glycated hemoglobin greater than 12%,; Aphakia in the studied eye,; Fibrosis or retrofoveolar retinal atrophy of the eye studied,; Tearing of the pigment epithelium reaching my macula of the studied eye,; Choroidal neovascularization unrelated to AMD,; Diabetic retinopathy and / or diabetic maculopathy proven,; Pregnant or lactating women,; Intraocular pressure> 25mmHg despite two hypotonizing treatments in eye drops,; Patient under tutorship or curatorship or private public law.